For Media: UK Press Releases
This page contains resources intended for journalists only. For media enquiries about our press releases please contact ukmediaenquiries@bayer.com
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
Bayer submits application to MHRA for elinzanetant to treat moderate to severe vasomotor systems associated with menopause in women
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with a common form of heart failure with high unmet medical need
Darolutamide meets primary endpoint in Phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flushes associated with menopause in women